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Hemorrhagic shock 
as a complication of       
anticoagulant therapy 
following the mitral valve 
replacement
ABSTRACT
This report describes a case of the hemorrhagic shock in a patient on the anticoagulant therapy supplementing implanted 
mechanical prosthetic heart valve replacing the mitral valve. The association between hemorrhagic shock, mechanical 
prosthetic heart valve and anticoagulant therapy is briefly discussed.
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Introduction
It is recommended that all patients with 
mechanical prosthetic heart valves 
receive oral anticoagulants (grade 
1C+) and that UFH or LMWH be given 
until the INR is within therapeutic range 
for 2 consecutive days (grade 2C). In 
patients with mechanical prosthetic 
heart valve in mitral position the goal INR 
is 3.0; range 2.5 to 3.5, alternative goal 
INR 2.5; range 2.0 to 3.0; and aspirin 
therapy (80 to 100 mg/d) (grade 2C). 
(1).  Bleeding is the major complication 
of anticoagulant therapy. (2).  The 
major determinants of bleeding from 
the use of oral anticoagulants are the 
intensity of the anticoagulant effect, 
individual response of the patient, 
and the extent of therapy. Patient 
characteristics associated with a major 
risk of hemorrhage have been identified 
in a number of randomized studies (3, 
4). In selecting therapy, the potential 
decrease in risk for thromboembolism 
must be balanced against probability 
of risk for bleeding. (1). 
Hemorrhagic shock is a potentially 
life-threatening condition that requires 
immediate treatment. The term shock 
denotes circulatory failure leading to 
an inadequate vital organ perfusion 
and oxygen delivery. The physiologic 
hallmark of the hypovolemic shock is 
decreased venous return to the heart 
and consequently decreased stroke 
volume, cardiac output, and systemic 
blood pressure. The mainstay of therapy 
is intravenous fluid resuscitation and 
transfusion along with treatment of 
underlying cause of shock. 
Case report
A 59-year-old man presented to 
the Department of anesthesiology, 
reanimatology and intensive care with 
signs of hemorrhagic shock. Prior to 
his admition, he was hospitalized in the 
University hospital for infective diseases 
(24th April- 30th May 2006) for treatment 
of bacterial endocarditis. From 31st May 
to 13th June 2006 he was hospitalized in 
the University Hospital Dubrava for the 
replacement of insufficient mitral valve 
with a prosthetic valve. Postoperatively, 
he received an anticoagulant therapy 
(heparin). Following this, between the 7 
th May and 13thMay 2006, in University 
hospital for infective diseases he received 
per oral anticoagulant therapy (pelentan) 
according to INR. On 13th June he was 
transferred to the Gastroenterology 
ward of the University Hospital Zagreb 
because of hematemesis and melena. 
The bleeding was detected using the 
emergency esofagogastroduodenos
copy (sclerosation and fibrin glue). In 
following days, he was in few occasions 
treated applying the same procedure. 
On the 18th of June, as the heeling of 
the ulcer was verified, the anticoagulant 
therapy started with enoxaparin 2*0,6 
ml s.c., pantoprazol 2*40 mg iv, special 
ulcer diet and amoxicillin + clavulonic 
acid  1,2 g i.v.and gentamicin 80 mg i.v. 
Next day he presented with nausea, 
fatigue and melena. Bleeding could not 
be stopped with emergency esofagog
astroduodenoscopy. Therefore he was 
transferred to the University Hospital of 
anesthesiology and intensive care. On 
examination, the patient was in severe 
distress, with vital signs as follows: 
temperature 36.0°C, blood pressure 
80/50 mmHg, heart rate of 130 beats/
min, respiratory rate of 24 breaths/min 
and oxygen saturation of 94% on room 
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air. He was pale, sweating, with cold 
cyanotic limbs, had delayed capillary 
refill, diminished pulses, and decreased 
skin temperature. CVP was 11 mmHg, 
the urine output was decreased (400 
ml) and he had hemi paresis of left side 
of the body. Findings on respiratory 
and abdominal examination were 
unremarkable. Laboratory findings 
were as following: hematocrit 0,17; 
hemoglobin 56 g/L; platelets 61; PT 0,53; 
PTT 50,0. Given the signs and symptoms 
of hemorrhagic shock the patient was 
treated with 2260 ml red blood cells, 
810 ml fresh frozen plasma, 2000 ml 
Sol. Ringer, 1000 ml  0,9% NaCl, 500 ml 
6% HAES and resection of stomach-Bill 
Roth II. He was discharged on 24th June 
2006 and continued to do well.
Discussion 
and conclusion
Patients with mechanical prosthetic 
heart valves, because of their thrombo-
genicity, need to receive anticoagulants 
(1). The main complication of this 
therapy is bleeding occurring in 6% 
to 39% of patients. (2). In patients with 
mechanical prosthetic heart valve in 
mitral position a goal INR is 3.0; range 
2.5 to 3.5 (grade 2C) (1).  Risk factors 
for bleeding are: liver or renal disease, 
alcoholism, malignant disease, age 
over 75, reduction in number/function 
of platelets, uncontrolled hypertension, 
anemia, history of a cerebrovascular 
insult and genetic factors. This case 
report describes a case of patient who 
developed a gastrointestinal bleeding 
while taking warfarin following the 
implantation of a mechanical prosthetic 
valve. His past medical history included 
hypertension which was poorly con-
trolled because he was not taking any 
antihypertensive drugs and also had 
cerebrovascular insult in May 2005. He 
was taking warfarin after the implan-
tation of mechanical prosthetic valve in 
the mitral position, but optimization of his 
international normalized ratio (INR) had 
been difficult to achieve. Also, he did 
not receive any anti-ulcer prophylaxis 
at the same time. In addition to warfarin, 
his medications included amoxicillin 
in combination with clavulonic acid. 
It should be mentioned here that for 
prophylaxis of the endocarditis he 
should have received an alternative 
antibiotic treatment because it is well 
known that amoxicillin in combination 
with clavulonic acid prolongs bleeding 
time and PT. The most interesting issue 
is optimization of anticoagulant therapy 
in this case. Because of the bleeding the 
therapy was stopped, which placed the 
patient at higher risk of thromboembolic 
complications. Also, the use of frac-
tioned heparin has advantage in com-
parison to LMWH (enoxaparin (5)) in 
way of better control of effect plus po-
ssibility of conversion. 
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